MaxQ AI’s ICH and stroke software to be available on Philips CT systems

MaxQ AI has announced that its AI-based intracranial hemorrhage (ICH) and stroke software will soon be integrated into Philips CT scanners. The first round of deployments is expected in 2020.

MaxQ AI’s Accipio ICH and stroke platform uses deep learning to evaluate medical images and automatically identify those that show signs of ICH. The platform will be available for the newest line of Philips CT systems and can be installed as an upgrade to existing equipment.

“Through this powerful collaboration, we will empower physicians to better identify and prioritize patients with a suspected ICH, which have the potential to save lives, improve the quality of care, and lower healthcare costs,” Gene Saragnese, CEO of MaxQ AI, said in a prepared statement.

“We are advancing patient care by co-creating with our customers to bring innovations in CT system design, workflow, radiation dose management, image quality, advanced clinical applications and improved total cost of ownership,” Karim Boussebaa, general manager of computed tomography and advanced molecular imaging at Philips, said in the same statement. “As healthcare continues to transform from a volume- to a value-based approach, and the amount of data available for each clinical decision dramatically grows, the integration of MaxQ's Accipio AI-powered solutions with our CT systems supports our ambition to achieve the quadruple aim: improved outcomes, enhanced patient experience, increased staff satisfaction, and lowered cost of care delivery.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup